NNC2215

NNC2215 is a bioengineered glucose-sensitive insulin. The drug is designed by a team of Novo Nordisk researchers.^[1]

NNC2215 can sense the glucose concentration presence in blood. The protein's sensitivity is reduced when low concentration of glucose, thus reducing the risk of hypoglycemia.^[2] In addition, it can effectively cover the risk of fluctuations of blood sugar levels.

The study was published on scientific journal Nature on October 16, 2024.^[3] This study demonstrated the ability of protein engineering in future medicine and a major advancement in treatment capabilities.

History

A glucose sensitive treatment method for diabetes have long been pursued by science since 1979.^[4] Such protein is expected to solve the problem of fluctuations of blood sugar levels. For diabetes patients, skipping meal alone could lead to hypoglycemia, which is a common complication that could cause loss of consciousness or seizures.^[5]

There are several attempts to create such a medicine with various levels of success.^[6][7]

See also

• Diabetes
• Hyperglycemia
• Hypoglycemia